The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) has been given a consensus rating of “Hold” by the five research ...

Colon cancer continues to be one of the leading causes of cancer-related deaths worldwide, with poor dietary habits ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Colon cancer continues to be one of the leading causes of cancer-related deaths worldwide, with poor dietary habits identified as a major risk factor ...

A new study has revealed that ferulic acid, a natural compound found in various plant-based foods, can significantly inhibit the growth and migration of colon cancer cells at different stages of ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ...

另外，在颞下颌关节的生长发育过程中，有一条神秘的信号通路 ——Notch1/Hes1 信号通路。它在关节软骨的细胞增殖、分化等过程中发挥着重要作用。可是，当生长过程中出现不对称的咬合负荷时，这条信号通路在颞下颌关节髁突软骨中的表现如何，几乎没人研究过。还有关节盘，它是颞下颌关节里主要的应力分布组织，就像一个 ...

Pidcock delivers big win as he squares off against a deep field at the five-day Ruta del Sol in southern Spain.

Stock analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) in a research note issued on Tuesday. The brokerage set a “sell” rating on the stock.

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...